Ignite Creation Date:
2025-12-24 @ 3:40 PM
Ignite Modification Date:
2026-01-01 @ 7:24 PM
Study NCT ID:
NCT00636792
Status:
COMPLETED
Last Update Posted:
2012-01-13
First Post:
2008-03-11
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma
Sponsor:
Millennium Pharmaceuticals, Inc.
Organization: